Plasma protein lipofuscin-like fluorophores in men with coronary artery disease treated with statins.
BACKGROUND
Lipid oxidation products react with protein to produce lipofuscin-like fluorophores (P-LLF) and modified apolipoprotein B that is an important element of the atherogenic properties of oxidized low-density lipoprotein (oxLDL). The aim of this study was to compare plasma concentrations of P-LLF between men with coronary artery disease (CAD) treated with statin drugs and healthy controls and to identify determinants of P-LLF.


METHODS
Plasma markers of protein modification including P-LLF and oxidized low-density lipoprotein-4E6 (oxLDL-4E6), low-density lipoprotein-conjugated dienes (LDL-CD), lipid peroxides, apolipoprotein B, and serum albumin were measured in 24 men with CAD who were receiving statin therapy and 20 healthy men in the same age range.


RESULTS
Plasma P-LLF (+23%, p = 0.001) was significantly higher and plasma oxLDL-4E6 (-33%, p <0.001) and apolipoprotein B (apoB) (-30%, p <0.001) concentrations were significantly lower in men with CAD compared with controls. Plasma P-LLF concentration was correlated significantly with plasma apoB (r = -0.596, p <0.001), serum albumin (r = 0.518, p <0.001), and age (r = 0.390, p = 0.009) and these variables were independent predictors of P-LLF in the study population. Plasma P-LLF was no longer significantly higher in men with CAD when plasma apoB concentration was taken into account.


CONCLUSIONS
Plasma P-LLF concentration is abnormally high and appears to be closely associated with lower levels of apoB in men with CAD receiving statin therapy. ApoB may be a preferential target of reactive aldehydic lipid oxidation products and a decrease in apoB may increase the quantity of these products available for condensation with albumin.
Sutherland
Wayne H
WH
Department of Medical and Surgical Sciences, University of Otago, Dunedin, New Zealand. wayne.sutherland@stonebow.otago.ac.nz
Williams
Michael J
MJ
de Jong
Sylvia A
SA
D000368:Aged; D001055:Apolipoproteins B / Q000097:blood; D015415:Biomarkers / Q000097:blood; D003324:Coronary Artery Disease / Q000097:blood* / Q000188:drug therapy* / Q000209:etiology; D005456:Fluorescent Dyes; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D015227:Lipid Peroxidation; D008062:Lipofuscin / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D012709:Serum Albumin / Q000032:analysis
D001055:Apolipoproteins B; D015415:Biomarkers; D005456:Fluorescent Dyes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008062:Lipofuscin; D008077:Lipoproteins, LDL; D012709:Serum Albumin; C099252:oxidized low density lipoprotein